Article Contents ::
- 1 Details About Generic Salt :: Diethylp
- 2 Main Medicine Class:: CNS stimulant,Anorexiant
- 3 (die-ETH-uhl-PRO-pee-ahn HIGH-droe-KLOR-ide) Tenuate Tablets: 25 mg Tenuate Dospan Tablets, sustained-release: 75 mg Nobesine Class: CNS stimulant/Anorexiant Indications Short-term (few weeks) adjunct to diet plan to reduce weight. Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent with or within 14 days of MAOI use; coadministration with other CNS stimulants. Route/Dosage ADULTS: PO 25 mg tid, 1 hr before meals. Sustained-release tablets: 75 mg once daily, in mid-morning. Interactions Guanethidine: May decrease hypotensive effect. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Selective serotonin reuptake inhibitors: Sympathomimetic effects of diethylpropion may be increased; increased risk of “serotonin syndrome.” Tricyclic antidepressants: May decrease anorexiant effect. Lab Test Interferences None well documented. Adverse Reactions CARDIOVASCULAR: Palpitations; tachycardia; arrhythmias; hypertension; hypotension. CNS: Overstimulation; dizziness; insomnia; euphoria; tremor; headache. DERMATOLOGIC: Excessive sweating; flushing. EENT: Mydriasis; blurred vision. GI: Dry mouth; unpleasant taste; nausea; diarrhea; constipation; stomach pain. GU: Dysuria; urinary frequency; impotence; menstrual disturbances. HEMATOLOGIC: Bone marrow depression; agranulocytosis; leukopenia. OTHER: Hair loss; myalgia; gynecomastia; allergic reactions (eg, urticaria; rash; erythema). Precautions Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Not recommended in children < 16 yr. Cardiovascular effects: May cause or aggravate hypertension or arrhythmias. Convulsions: Diethylpropion may aggravate; dose titration or discontinuance may be necessary. Drug dependence: Related to amphetamine; has abuse potential. Tolerance: Tolerance may occur. PATIENT CARE CONSIDERATIONS Administration/Storage Give medication 1 hr before meals. Give sustained-release tablets once daily at mid-morning. Do not crush or open sustained-release tablets. Assessment/Interventions Obtain patient history, including drug history and any known allergies. Assess physical and psychological status throughout therapy. Measure patient’s weight weekly. Notify health care provider and withhold medication if there is a BP increase of 20 mm Hg or if heart dysrhythmia or increase in heart rate develop. OVERDOSAGE: SIGNS & SYMPTOMS Restlessness, tremor, hyperreflexia, fever, tachypnea, dizziness, panic, aggression, hallucinations, seizure, coma, arrhythmias, hypotension, hypertension, death Patient/Family Education Explain potential for increased agitation, palpitations, and dizziness, and identify precaution to take when performing tasks that require physical coordination or mental concentration. Tell patient to record weight weekly. Explain that drug will make patient feel less hungry and thus make it easier to adhere to diet but that weight loss will occur only with calorie reduction and increased physical activity. Instruct patient on missed medication procedure: if < 2 hr, take medication; if > 2 hr, wait until next scheduled dose. Do not double up on medication. Advise patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks. Identify techniques to prevent or treat dry mouth. –>
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Diethylp
Main Medicine Class:: CNS stimulant,Anorexiant
(die-ETH-uhl-PRO-pee-ahn HIGH-droe-KLOR-ide)
Tenuate
Tablets: 25 mg
Tenuate Dospan
Tablets, sustained-release: 75 mg
Nobesine
Class: CNS stimulant/Anorexiant
Indications Short-term (few weeks) adjunct to diet plan to reduce weight.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent with or within 14 days of MAOI use; coadministration with other CNS stimulants.
Route/Dosage
ADULTS: PO 25 mg tid, 1 hr before meals. Sustained-release tablets: 75 mg once daily, in mid-morning.
Interactions
Guanethidine: May decrease hypotensive effect. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Selective serotonin reuptake inhibitors: Sympathomimetic effects of diethylpropion may be increased; increased risk of “serotonin syndrome.” Tricyclic antidepressants: May decrease anorexiant effect.
Lab Test Interferences None well documented.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; arrhythmias; hypertension; hypotension. CNS: Overstimulation; dizziness; insomnia; euphoria; tremor; headache. DERMATOLOGIC: Excessive sweating; flushing. EENT: Mydriasis; blurred vision. GI: Dry mouth; unpleasant taste; nausea; diarrhea; constipation; stomach pain. GU: Dysuria; urinary frequency; impotence; menstrual disturbances. HEMATOLOGIC: Bone marrow depression; agranulocytosis; leukopenia. OTHER: Hair loss; myalgia; gynecomastia; allergic reactions (eg, urticaria; rash; erythema).
Precautions
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Not recommended in children < 16 yr. Cardiovascular effects: May cause or aggravate hypertension or arrhythmias. Convulsions: Diethylpropion may aggravate; dose titration or discontinuance may be necessary. Drug dependence: Related to amphetamine; has abuse potential. Tolerance: Tolerance may occur.
PATIENT CARE CONSIDERATIONS
Administration/Storage
- Give medication 1 hr before meals. Give sustained-release tablets once daily at mid-morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess physical and psychological status throughout therapy.
- Measure patient’s weight weekly.
- Notify health care provider and withhold medication if there is a BP increase of 20 mm Hg or if heart dysrhythmia or increase in heart rate develop.
OVERDOSAGE: SIGNS & SYMPTOMS
Restlessness, tremor, hyperreflexia, fever, tachypnea, dizziness, panic, aggression, hallucinations, seizure, coma, arrhythmias, hypotension, hypertension, death
Patient/Family Education
- Explain potential for increased agitation, palpitations, and dizziness, and identify precaution to take when performing tasks that require physical coordination or mental concentration.
- Tell patient to record weight weekly.
- Explain that drug will make patient feel less hungry and thus make it easier to adhere to diet but that weight loss will occur only with calorie reduction and increased physical activity.
- Instruct patient on missed medication procedure: if < 2 hr, take medication; if > 2 hr, wait until next scheduled dose. Do not double up on medication.
- Advise patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Identify techniques to prevent or treat dry mouth.
–>
PATIENT CARE CONSIDERATIONS
OVERDOSAGE: SIGNS & SYMPTOMS | |
Restlessness, tremor, hyperreflexia, fever, tachypnea, dizziness, panic, aggression, hallucinations, seizure, coma, arrhythmias, hypotension, hypertension, death |
Drugs Class ::
(die-ETH-uhl-PRO-pee-ahn HIGH-droe-KLOR-ide) |
Tenuate |
Tablets: 25 mg |
Tenuate Dospan |
Tablets, sustained-release: 75 mg |
Nobesine |
Class: CNS stimulant/Anorexiant |
Indications for Drugs ::
Indications Short-term (few weeks) adjunct to diet plan to reduce weight.
Drug Dose ::
Route/Dosage
ADULTS: PO 25 mg tid, 1 hr before meals. Sustained-release tablets: 75 mg once daily, in mid-morning.
Contraindication ::
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent with or within 14 days of MAOI use; coadministration with other CNS stimulants.
Drug Precautions ::
Precautions
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Not recommended in children < 16 yr. Cardiovascular effects: May cause or aggravate hypertension or arrhythmias. Convulsions: Diethylpropion may aggravate; dose titration or discontinuance may be necessary. Drug dependence: Related to amphetamine; has abuse potential. Tolerance: Tolerance may occur.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; arrhythmias; hypertension; hypotension. CNS: Overstimulation; dizziness; insomnia; euphoria; tremor; headache. DERMATOLOGIC: Excessive sweating; flushing. EENT: Mydriasis; blurred vision. GI: Dry mouth; unpleasant taste; nausea; diarrhea; constipation; stomach pain. GU: Dysuria; urinary frequency; impotence; menstrual disturbances. HEMATOLOGIC: Bone marrow depression; agranulocytosis; leukopenia. OTHER: Hair loss; myalgia; gynecomastia; allergic reactions (eg, urticaria; rash; erythema).
Drug Mode of Action ::
(die-ETH-uhl-PRO-pee-ahn HIGH-droe-KLOR-ide) |
Tenuate |
Tablets: 25 mg |
Tenuate Dospan |
Tablets, sustained-release: 75 mg |
Nobesine |
Class: CNS stimulant/Anorexiant |
Drug Interactions ::
Interactions
Guanethidine: May decrease hypotensive effect. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Selective serotonin reuptake inhibitors: Sympathomimetic effects of diethylpropion may be increased; increased risk of “serotonin syndrome.” Tricyclic antidepressants: May decrease anorexiant effect.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess physical and psychological status throughout therapy.
- Measure patient’s weight weekly.
- Notify health care provider and withhold medication if there is a BP increase of 20 mm Hg or if heart dysrhythmia or increase in heart rate develop.
|
Drug Storage/Management ::
Administration/Storage
- Give medication 1 hr before meals. Give sustained-release tablets once daily at mid-morning.
- Do not crush or open sustained-release tablets.
Drug Notes ::
Patient/Family Education
- Explain potential for increased agitation, palpitations, and dizziness, and identify precaution to take when performing tasks that require physical coordination or mental concentration.
- Tell patient to record weight weekly.
- Explain that drug will make patient feel less hungry and thus make it easier to adhere to diet but that weight loss will occur only with calorie reduction and increased physical activity.
- Instruct patient on missed medication procedure: if < 2 hr, take medication; if > 2 hr, wait until next scheduled dose. Do not double up on medication.
- Advise patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Identify techniques to prevent or treat dry mouth.
–>